Proto-oncogene PML and Tumor Evasion in Prostate Cancer
Abstract
The peptides presented by class I human leukocyte antigen (HLA) are the primary targets on tumor cells for immune recognition by host cytotoxic T lymphocytes (CTL). Tumors can therefore avoid CTL recognition by down-regulation of cell surface HLA. However, the molecular mechanism of HLA down-regulation and its significance in progression of prostate carcinoma have not been determined. We have proposed to identify the antigen presentation defects in prostate cancer, to examine the role of proto-oncogene PML in HLA class I down regulation in prostate cancer, and to study the immune regulation in experimental transgenic murine prostate cancer (TRAMP) models. In the past funding period, we have performed immunohistochemical study to show the concordant proto-oncogene PML and HLA class I antigen down-regulation in surgically removed prostate cancer lesions We have examined the proto-oncogene PML isoform expression and antigen presentation gene expression in prostate cancer cell lines. Most importantly, we made the important discovery that thymic deletion is the major mechanism of T cell immune tolerance in TRAMP mouse model. We believe that these works will open new revenues for prostate cancer immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2000
- Accession Number
- ADA392318
Entities
People
- Pan Zheng
Organizations
- Ohio State University